Researchers from the Memorial Sloan Kettering Cancer Center (MSK) have introduced a new open-source computational method, named Spectra, aimed at enhancing the analysis of single-cell transcriptomic data. The primary goal of Spectra is to enhance the understanding of interactions between different cells, such as the connections between cancer cells and immune cells, which holds significant potential for enhancing immunotherapy treatments.
The recently published work in Nature Biotechnology details how Spectra can sift through technical distractions to pinpoint functionally pertinent gene expression programs. Some of these programs might be new or particularly significant in specific biological contexts. The MSK research briefing highlights the algorithm's potential in studying vast patient data to discern patient characteristics that hold clinical importance. Notably, the method seems primed for discovering biomarkers and potential drug targets in the growing area of immuno-oncology.
The MSK team has generously made the Spectra tool available for global researchers. Study senior author Dana Pe’er, PhD, who leads the Computational and Systems Biology Program at MSK’s Sloan Kettering Institute, stated, “Every single tool I build, I strive to make robust so it can be used in many contexts, not just one. I also try and make them as accessible as possible.” She further expressed her joy in creating a foundational tool for the broader community to facilitate multiple biological discoveries.
Dr. Pe’er mentioned that in addition to the MSK team, researchers from various institutions are employing Spectra to study multiple diseases.
The capability of single-cell technologies to scrutinize individual cells in tissue samples has drastically advanced our understanding of health and diseases over the last decade. This advancement has provided a deeper understanding of cell adaptability and responses in various health situations, including cancer treatment resistance. However, the sheer volume of data produced by these methods can be overwhelming, leading to difficulties in accurate interpretation, especially in the context of understanding gene programs in multiple cell types.
Highlighting the importance of the MSK team’s work, Dr. Pe’er said, “This is especially important for studying the interactions between cancer cells and immune cells, which involve highly overlapping gene programs.”
A collaborative effort from researchers skilled in statistics, computational biology, and immunology, Spectra was developed to simplify the complexity of biology. For their research, the team used Spectra on data from breast cancer immunotherapy and a lung cancer atlas, representing over 1.5 million cells from 375 participants across 21 studies. This showcased Spectra’s capabilities in superseding the constraints of traditional analyses.
The power of Spectra lies in its utilization of pre-existing scientific knowledge—libraries of gene programs curated by experts. Spectra can then adapt to the given data, helping identify new and evolving gene programs. In their study, this feature helped the scientists identify a new cancer invasion program.
Furthermore, Spectra’s design considers genes that define varying cell types, which aids in recognizing gene programs related to cellular functions. Dr. Pe’er mentioned how Spectra aids in distinguishing T cells based on their activity against a person’s cancer.
The tool's capacity to apply findings from one dataset to another can accelerate discoveries, allowing scientists to expand knowledge across single-cell sequencing studies without intricate data amalgamation.
The recently published work in Nature Biotechnology details how Spectra can sift through technical distractions to pinpoint functionally pertinent gene expression programs. Some of these programs might be new or particularly significant in specific biological contexts. The MSK research briefing highlights the algorithm's potential in studying vast patient data to discern patient characteristics that hold clinical importance. Notably, the method seems primed for discovering biomarkers and potential drug targets in the growing area of immuno-oncology.
The MSK team has generously made the Spectra tool available for global researchers. Study senior author Dana Pe’er, PhD, who leads the Computational and Systems Biology Program at MSK’s Sloan Kettering Institute, stated, “Every single tool I build, I strive to make robust so it can be used in many contexts, not just one. I also try and make them as accessible as possible.” She further expressed her joy in creating a foundational tool for the broader community to facilitate multiple biological discoveries.
Dr. Pe’er mentioned that in addition to the MSK team, researchers from various institutions are employing Spectra to study multiple diseases.
The capability of single-cell technologies to scrutinize individual cells in tissue samples has drastically advanced our understanding of health and diseases over the last decade. This advancement has provided a deeper understanding of cell adaptability and responses in various health situations, including cancer treatment resistance. However, the sheer volume of data produced by these methods can be overwhelming, leading to difficulties in accurate interpretation, especially in the context of understanding gene programs in multiple cell types.
Highlighting the importance of the MSK team’s work, Dr. Pe’er said, “This is especially important for studying the interactions between cancer cells and immune cells, which involve highly overlapping gene programs.”
A collaborative effort from researchers skilled in statistics, computational biology, and immunology, Spectra was developed to simplify the complexity of biology. For their research, the team used Spectra on data from breast cancer immunotherapy and a lung cancer atlas, representing over 1.5 million cells from 375 participants across 21 studies. This showcased Spectra’s capabilities in superseding the constraints of traditional analyses.
The power of Spectra lies in its utilization of pre-existing scientific knowledge—libraries of gene programs curated by experts. Spectra can then adapt to the given data, helping identify new and evolving gene programs. In their study, this feature helped the scientists identify a new cancer invasion program.
Furthermore, Spectra’s design considers genes that define varying cell types, which aids in recognizing gene programs related to cellular functions. Dr. Pe’er mentioned how Spectra aids in distinguishing T cells based on their activity against a person’s cancer.
The tool's capacity to apply findings from one dataset to another can accelerate discoveries, allowing scientists to expand knowledge across single-cell sequencing studies without intricate data amalgamation.
